Drugs / MYL-1401H
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02479646 | Sep 2014 → Jun 2015 | — | Mylan Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02467868 | Mar → Sep 2015 | breast cancer, chemotherapy-induced toxicity | Mylan Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MYL-1401H | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02479646 ↗ |
| Route | Subcutaneous | “MYL-1401H: single subcutaneous injection (2mg)” NCT02479646 ↗ |